Promoting wellness for patients on androgen deprivation therapy: Why using numerous drugs for drug side effects should not be first-line treatment

Urologic Clinics of North America

Volumn 38, Issue 3, 2011, Pages 303-312

  Moyad, Mark A ^a,b   Roach, Mack ^c  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b EISENHOWER MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Androgen deprivation therapy; Prostate cancer; Side effects; Toxicity

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; AMINO ACID; ANTIANDROGEN; CALCIUM; CALCIUM CARBONATE; CYPROTERONE ACETATE; DENOSUMAB; DOCOSAPENTAENOIC ACID; FISH OIL; HEMOGLOBIN; HERBACEOUS AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; OMEGA 3 FATTY ACID; PLACEBO; PRAVASTATIN; PROTEIN; SIMVASTATIN; TESTOSTERONE; VENLAFAXINE; VITAMIN D; ZOLEDRONIC ACID;

ANDROGEN DEPRIVATION THERAPY; ANDROGEN THERAPY; BONE METASTASIS; CALCIUM DEFICIENCY; CALCIUM INTAKE; CARDIOVASCULAR RISK; DIET SUPPLEMENTATION; DIETARY INTAKE; DISEASE SEVERITY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EXERCISE; FATIGUE; FRAGILITY FRACTURE; HOT FLUSH; HUMAN; HYPOCALCEMIA; JAW OSTEONECROSIS; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MACROCYTIC ANEMIA; MICROCYTIC ANEMIA; MUSCLE ATROPHY; MUSCLE DISEASE; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PATIENT CARE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN INTAKE; REVIEW; SIDE EFFECT; VITAMIN D DEFICIENCY; VITAMIN INTAKE; WELLBEING;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DISEASES, METABOLIC; CARDIOVASCULAR DISEASES; FATIGUE; HOT FLASHES; HUMANS; MALE; MENTAL DISORDERS; MUSCULAR DISEASES; OSTEOPOROSIS; PROSTATIC NEOPLASMS;

EID: 79960631409     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2011.05.001     Document Type: Review

References (91)

1. Sharifi N., Gulley J.L., Dahut W.L. An update on androgen therapy for prostate cancer. Endocr Relat Cancer 2010, 17:R305-R315.
2. Wilson A.C., Meethal S.V., Bowen R.L., et al. Leuprolide acetate: a drug of diverse clinical applications. Expert Opin Investig Drugs 2007, 16:1851-1863.
3. Mottet N., Bellmunt J., Bolla M., et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011, 59:572-583.
4. Adler R.A. Management of osteoporosis in men on androgen deprivation therapy. Maturitas 2011, 68:143-147.
5. Beebe-Dimmer J., Morgenstern H., Cetin K., et al. Androgen deprivation therapy and cataract incidence among elderly prostate cancer patients in the United States. Ann Epidemiol 2011, 21:156-163.
6. Kim H.S., Freedland S.J. Androgen deprivation therapy in prostate cancer: anticipated side-effects and their management. Curr Opin Support Palliat Care 2010, 4:147-152.
7. Saylor P.J., Keating N.L., Smith M.R. Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy. J Gen Intern Med 2009, 24(Suppl 2):S389-S394.
8. Moyad M.A. Promoting general health during androgen deprivation therapy (ADT): a rapid 10-step review for your patients. Urol Oncol 2005, 23:56-64.
9. Strum S.B., McDermed J.E., Scholz M.C., et al. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 1997, 79:933-941.
10. Malone S., Perry G., Segal R., et al. Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II study. BJU Int 2005, 96:514-520.
11. Nilsson-Ehle H., Jagenburg R., Landahl S., et al. Blood hemoglobin declines in the elderly: implications for reference intervals from age 70 to 88. Eur J Haematol 2000, 65:297-305.
12. Ferrucci L., Maggio M., Bandinelli S., et al. Low testosterone levels and the risk of anemia in older men and women. Arch Intern Med 2006, 166:1380-1388.
13. Hara N., Nishiyama T., Takizawa I., et al. Decline of the red blood cell count in patients receiving androgen deprivation therapy for localized prostate cancer: impact of ADT on insulin-like growth factor-1 and erythropoiesis. Urology 2010, 75:1441-1445.
14. Borst S.E., Mulligan T. Testosterone replacement therapy for older men. Clin Interv Aging 2007, 2:561-566.
15. Galvao D.A., Nosaka K., Taaffe D.R., et al. Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc 2006, 38:2045-2052.
16. Curtis K.K., Adam T.J., Chen S.C., et al. Anaemia following initiation of androgen deprivation therapy for metastatic prostate cancer: a retrospective chart review. Aging Male 2008, 11:157-161.
17. Diamond T.H., Higan C.S., Smith M.R., et al. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 2004, 100:892-899.
18. Wang W., Yussa T., Tsuchiya N., et al. Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy. Endocr Relat Cancer 2008, 15:943-952.
19. Yuasa T., Maita S., Tsuchiya N., et al. Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients. Urology 2010, 75:1131-1137.
20. Iso H. Lifestyle and cardiovascular disease in Japan. J Atheroscler Thromb 2011, 18:83-88.
21. Ryan C.W., Huo D., Stallings J.W., et al. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy. Urology 2007, 70:122-126.
22. Planas J., Morote J., Orsola A., et al. The relationship between daily calcium intake and bone mineral density in men with prostate cancer. BJU Int 2007, 99:812-815.
23. Wilcox A., Carnes M.L., Moon T.D., et al. Androgen deprivation in veterans with prostate cancer: implications for skeletal health. Ann Pharmacother 2006, 40:2107-2114.
24. Panju A.H., Breunis H., Cheung A.M., et al. Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer. BJU Int 2009, 103:753-757.
25. Yee E.F., White R.E., Murata G.H., et al. Osteoporosis management in prostate cancer patients treated with androgen deprivation therapy. J Gen Intern Med 2007, 22:1305-1310.
26. Smith M.R., Eastham J., Gleason D., et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003, 169:2008-2012.
27. Ryan C.W., Huo D., Demers L.M., et al. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol 2006, 176:972-978.
28. Greenspan S.L., Nelson J.B., Trump D.L., et al. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007, 146:416-424.
29. Smith M.R., Egerdie B., Harnandez Toriz N., et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009, 361:745-755.
30. Khosla S. Increasing options for the treatment of osteoporosis. N Engl J Med 2009, 361:818-820.
31. Fizazi K., Carducci M., Smith M., et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study. Lancet 2011, 377:813-822.
32. Reid I.R., Ames R., Mason B., et al. Randomized controlled trial of calcium supplementation in healthy, nonosteoporotic, older men. Arch Intern Med 2008, 168:2276-2282.
33. Chel V., Wijnhoven H.A., Smit J.H., et al. Efficacy of different doses and time intervals of oral vitamin D supplementation with or without calcium in elderly nursing home residents. Osteoporos Int 2008, 19:663-671.
34. Galvao D.A., Spry N.A., Taaffe D.R., et al. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int 2008, 102:44-47.
35. Galvao D.A., Taaffe D.R., Spry N., et al. Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis 2009, 12:198-203.
36. Galvao D.A., Taaffe D.R., Spry N., et al. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol 2010, 28:340-347.
37. Braith R.W., Stewart K.J. Resistance exercise training: its role in the prevention of cardiovascular disease. Circulation 2006, 113:2642-2650.
38. Kukuljan S., Nowson C.A., Sanders K.M., et al. Independent and combined effects of calcium-vitamin d3 and exercise on bone structure and strength in older men: an 18-month factorial design randomized controlled trial. J Clin Endocrinol Metab 2011, 96:955-963.
39. Roubenoff R. Sarcopenia: a major modifiable cause of frailty in the elderly. J Nutr Health Aging 2000, 4:140-142.
40. von Haehling S., Morley J.E., Anker S.D. An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachex Sarcopenia Muscle 2010, 1:129-133.
41. Scott D., Blizzard L., Fell J., et al. A prospective study of the associations between 25-hydroxy-vitamin D, sarcopenia progression and physical activity in older adults. Clin Endocrinol 2010, 73:581-587.
42. Wolfe R.R., Miller S.L., Miller K.B. Optimal protein intake in the elderly. Clin Nutr 2008, 27:675-684.
43. Wolfe R.R., Miller S.L. The recommended dietary allowance of protein: a misunderstood concept. JAMA 2008, 299:2891-2893.
44. Gaffney-Stomberg E., Insogna K.L., Rodriguez N.R., et al. Increasing dietary protein requirements in elderly people for optimal muscle and bone health. J Am Geriatr Soc 2009, 57:1073-1079.
45. Borsheim E., Bui Q.U., Tissier S., et al. Effect of amino acid supplementation on muscle mass, strength and physical function in the elderly. Clin Nutr 2008, 27:189-195.
46. Scognamiglio R., Avogaro A., Negut C., et al. The effects of oral amino acid intake on ambulatory capacity in elderly subjects. Aging Clin Exp Res 2004, 16:443-447.
47. Dillon E.L., Sheffield-Moore M., Paddon-Jones D., et al. Amino acid supplementation increases lean body mass, basal muscle protein synthesis, and insulin-like growth factor-I expression in older women. J Clin Endocrinol Metab 2009, 94(5):1630-1637.
48. Pennings B., Boirie Y., Senden J.M., et al. Whey protein stimulates postprandial muscle protein accretion more effectively than do casein and casein hydrolysate in older men. Am J Clin Nutr 2011, 93:997-1005.
49. Schmitz K.H., Ahmed R.L., Troxel A.B., et al. Weight lifting for women at risk for breast cancer-related lymphedema: a randomized trial. JAMA 2010, 304:2699-2705.
50. Nair K.S., Rizza R.A., O'Brien P., et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006, 355:1647-1659.
51. Blackman M.R., Sorkin J.D., Munzer T., et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA 2002, 288:2282-2292.
52. Taaffe D.R., Pruitt L., Reim J., et al. Effect of recombinant growth hormone on the muscle strength response to resistance exercise in elderly men. J Clin Endocrinol Metab 1994, 79:1361-1366.
53. Smith G.I., Atherton P., Reeds D.N., et al. Dietary omega-3 fatty acid supplementation increases the rate of muscle protein synthesis in older adults: a randomized controlled trial. Am J Clin Nutr 2011, 93:402-412.
54. Levine G.N., D'Amico A.V., Berger P., et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 2010, 121:833-840.
55. Efstathiou J.A., Bae K., Shipley W.U., et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol 2008, 54:816-823.
56. Roach M., Bae K., Speight J., et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008, 26:585-591.
57. Denham J.W., Steigler A., Lamb D.S., et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 2011, 12(5):451-459.
58. Haseen F., Murray L.J., Cardwell C.R., et al. The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and meta-analysis. J Cancer Surviv 2010, 4:128-139.
59. Smith M.R., Lee H., McGovern F., et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer 2008, 112:2188-2194.
60. Eri L.M., Urdal P., Bechensteen A.G. Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. J Urol 1995, 154:100-104.
61. Yannucci J., Manola J., Garnick M.B., et al. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. J Urol 2006, 176:520-525.
62. Fetterman J.W., Zdanowicz M.M. Therapeutic potential of n-3 polyunsaturated fatty acids in disease. Am J Health Syst Pharm 2009, 66:1169-1179.
63. Taouis M., Dagou C., Ster C., et al. N-3 polyunsaturated fatty acids prevent the defect of insulin receptor signaling in muscle. Am J Physiol Endocrinol Metab 2002, 282:E664-E671.
64. Lombardo Y.B., Chicco A.G. Effects of dietary polyunsaturated n-3 fatty acids on dyslipidemia and insulin resistance in rodents and humans. A review. J Nutr Biochem 2006, 17:1-13.
65. Fedor D., Kelley D.S. Prevention of insulin resistance by n-3 polyunsaturated fatty acids. Curr Opin Clin Nutr Metab Care 2009, 12:138-146.
66. Carpenter Y.A., Portois L., Malaisse W.J. N-3 fatty acids and the metabolic syndrome. Am J Clin Nutr 2006, 83(Suppl):1499S-1504S.
67. Rudkowska I. Fish oil for cardiovascular disease: impact on diabetes. Maturitas 2010, 67:25-28.
68. Derweesh I.H., Diblasio C.J., Kincade M.C., et al. Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer. BJU Int 2007, 100:1060-1065.
69. Kris-Etherton P.M., Harris W.S., Appel L.J., et al. Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol 2003, 23:151-152.
70. Yokoyama M., Origasa H., Matsuzaki M., et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded endpoint analysis. Lancet 2007, 369:1090-1098.
71. Oikawa S., Yokoyama M., Origasa H., et al. Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: sub-analysis of the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 2009, 206:535-539.
72. Segal R.J., Reid R.D., Coumeya K.S., et al. Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol 2009, 27:344-351.
73. Barton D.L., Soori G.S., Bauer B.A., et al. Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA. Support Care Cancer 2010, 18:179-187.
74. Kontos M., Agbaje O.F., Rymer J., et al. What can be done about hot flushes after treatment for breast cancer?. Climacteric 2010, 13:4-21.
75. Moyad M.A. Complementary therapies for reducing the risk of osteoporosis in patients receiving luteinizing hormone-releasing hormone treatment/orchiectomy for prostate cancer: a review and assessment of the need for more research. Urology 2002, 59(4 Suppl 1):34-40.
76. Irani J., Salomon L., Oba R., et al. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomized trial. Lancet 2010, 11:147-154.
77. Langenstroer P., Kramer B., Cutting B., et al. Parenteral medroxyprogesterone for the management of luteinizing hormone releasing hormone induced hot flashes in men with advanced prostate cancer. J Urol 2005, 174:642-645.
78. Sullivan D.H., Roberson P.K., Smith E.S., et al. Effects of muscle strength training and megestrol acetate on strength, muscle mass, and function in frail older people. J Am Geriatr Soc 2007, 55:20-28.
79. Lambert C.P., Sullivan D.H., Evans W.J. Megesterol acetate-induced weight gain does not negatively affect blood lipids in elderly men: effects of resistance training and testosterone replacement. J Gerontol A Biol Sci Med Sci 2003, 58:644-647.
80. Lucas M., Asselin G., Merette C., et al. Effects of ethyl-eicosapentaenoic acid omega-3 fatty acid supplementation on hot flashes and quality of life among middle-aged women: a double-blind, placebo-controlled, randomized clinical trial. Menopause 2009, 16:357-366.
81. Freeman M.P. Omega-3 fatty acids in major depressive disorder. J Clin Psychiatry 2009, 70(Suppl 5):7-11.
82. Martins J.G. EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials. J Am Coll Nutr 2009, 28:525-542.
83. Wong R.W., Rabie B. Chinese red yeast rice (Monascus purpureus-fermented rice) promotes bone formation. Chin Med 2008, 3:4.
84. Majima T., Komatsu Y., Fukao A., et al. Short-term effects of atorvastatin on bone turnover in male patients with hypercholesterolemia. Endocr J 2007, 54:145-151.
85. Martin-Bautista E., Munoz-Torres M., Fonolla J., et al. Improvement of bone formation biomarkers after 1-year consumption with milk fortified with eicosapentaenoic acid, docosahexaenoic acid, oleic acid, and selected vitamins. Nutr Res 2010, 30:320-326.
86. Murphy R.A., Mourtzakis M., Chu Q.S., et al. Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer 2011, 117:1775-1782.
87. Murphy R.A., Mourtzakis M., Chu Q.S., et al. Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer. Cancer 2011, [Epub ahead of print]. 10.1002/cncr.25933.
88. Layman D.K., Evans E.M., Erickson D., et al. A moderate-protein diet produces sustained weight loss and long-term changes in body composition and blood lipids in obese adults. J Nutr 2009, 139:514-521.
89. Dhillon P.K., Kenfield S.A., Stampfer M.J., et al. Long-term aspirin use and the risk of total, high-grade, regionally advanced and lethal prostate cancer in a prospective cohort of health professionals, 1988-2006. Int J Cancer 2011, 128:2444-2452.
90. Rothwell P.M., Fowkes F.G., Belch J.F., et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomized trials. Lancet 2011, 377:31-41.
91. Antithrombotic Trialists' (ATT) Collaboration Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials. Lancet 2009, 373:1849-1860.